{"id":"lt3-liothyronine","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Heat intolerance"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LT3 is the active thyroid hormone that regulates metabolism, thermogenesis, and protein synthesis by binding to thyroid hormone receptors (TRα and TRβ) in target tissues. It is more potent and faster-acting than levothyroxine (T4), the inactive precursor. LT3 directly stimulates mitochondrial oxidative metabolism and increases oxygen consumption across multiple organ systems.","oneSentence":"Liothyronine is a synthetic form of triiodothyronine (T3) that binds to thyroid hormone receptors to increase metabolic rate and cellular energy production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:42.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypothyroidism (replacement therapy)"},{"name":"Myxedema coma (acute severe hypothyroidism)"}]},"trialDetails":[{"nctId":"NCT06731764","phase":"PHASE2, PHASE3","title":"Novel Approaches to the Treatment of Hypothyroidism","status":"RECRUITING","sponsor":"UConn Health","startDate":"2024-12-10","conditions":"Hypothyroidism","enrollment":90},{"nctId":"NCT07424183","phase":"PHASE2","title":"T4/T3 Therapy in Hypothyroidism","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-03","conditions":"Hypothyroidism Primary","enrollment":60},{"nctId":"NCT05682482","phase":"PHASE3","title":"LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.","status":"RECRUITING","sponsor":"M. Medici","startDate":"2022-10-07","conditions":"Autoimmune Hypothyroidism","enrollment":600},{"nctId":"NCT04111536","phase":"PHASE1, PHASE2","title":"Developing Oral LT3 Therapy for Heart Failure - HFpEF","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-03-08","conditions":"Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome","enrollment":28},{"nctId":"NCT04112316","phase":"PHASE1, PHASE2","title":"Developing Oral LT3 Therapy for Heart Failure - HFrEF","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-02-11","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome","enrollment":28},{"nctId":"NCT04782856","phase":"PHASE2","title":"Energy Metabolism in Thyroidectomized Patients","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2020-10-28","conditions":"Thyroid Goiter, Hypothyroidism, Thyroid Cancer","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":119,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intervention group LT4/LT3 combination therapy"],"phase":"phase_3","status":"active","brandName":"LT3 (liothyronine)","genericName":"LT3 (liothyronine)","companyName":"M. Medici","companyId":"m-medici","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liothyronine is a synthetic form of triiodothyronine (T3) that binds to thyroid hormone receptors to increase metabolic rate and cellular energy production. Used for Hypothyroidism (replacement therapy), Myxedema coma (acute severe hypothyroidism).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}